drugset

drugset / Trial / NCT06622941

Study to ONO-4538 in Patients With Rhabdoid Tumor

NCT06622941 ↗

Phase 2 Recruiting 23 enrolled Ono Pharmaceutical Co., Ltd.

NaSingle-groupOpen-labelTreatment

Summary

Investigate the efficacy and safety of ONO-4538 for the treatment of rhabdoid Tumors

Timeline

Start: 2024-11-25
Primary completion: 2029-01-31
Completion: 2030-03-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Nivolumab	Monoclonal antibody	—	—

Indications